| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 209 | 2025 | 459 | 33.070 |
Why?
|
| Neoplasms, Glandular and Epithelial | 30 | 2018 | 41 | 6.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 52 | 2025 | 1031 | 5.910 |
Why?
|
| Immunoconjugates | 16 | 2025 | 39 | 5.740 |
Why?
|
| Neoplasm Recurrence, Local | 35 | 2025 | 649 | 5.530 |
Why?
|
| Cystadenocarcinoma, Serous | 42 | 2024 | 73 | 5.380 |
Why?
|
| Endometrial Neoplasms | 28 | 2023 | 144 | 5.200 |
Why?
|
| Maytansine | 11 | 2025 | 11 | 4.290 |
Why?
|
| Antibodies, Monoclonal, Humanized | 23 | 2025 | 236 | 4.160 |
Why?
|
| Antineoplastic Agents | 31 | 2023 | 1222 | 3.660 |
Why?
|
| Gene Expression Profiling | 51 | 2021 | 1105 | 3.420 |
Why?
|
| Female | 282 | 2025 | 28171 | 3.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 80 | 2021 | 857 | 3.330 |
Why?
|
| Uterine Cervical Neoplasms | 18 | 2024 | 299 | 3.140 |
Why?
|
| Proto-Oncogene Proteins c-jun | 49 | 2011 | 75 | 3.060 |
Why?
|
| Drug Resistance, Neoplasm | 26 | 2025 | 326 | 3.030 |
Why?
|
| Humans | 368 | 2025 | 52483 | 2.740 |
Why?
|
| Folate Receptor 1 | 9 | 2025 | 27 | 2.520 |
Why?
|
| Transcription Factor AP-1 | 29 | 2013 | 61 | 2.370 |
Why?
|
| Peritoneal Neoplasms | 10 | 2021 | 65 | 2.330 |
Why?
|
| Molecular Targeted Therapy | 12 | 2021 | 133 | 2.080 |
Why?
|
| Aged | 105 | 2025 | 10121 | 2.070 |
Why?
|
| Fallopian Tube Neoplasms | 7 | 2025 | 15 | 1.970 |
Why?
|
| Paclitaxel | 25 | 2023 | 89 | 1.960 |
Why?
|
| Middle Aged | 114 | 2025 | 13028 | 1.890 |
Why?
|
| Adenocarcinoma, Clear Cell | 14 | 2019 | 34 | 1.840 |
Why?
|
| Prognosis | 46 | 2021 | 2099 | 1.780 |
Why?
|
| Neoplasm Staging | 43 | 2021 | 772 | 1.720 |
Why?
|
| Mutation | 37 | 2024 | 1347 | 1.650 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 30 | 2016 | 405 | 1.640 |
Why?
|
| Carboplatin | 22 | 2023 | 57 | 1.630 |
Why?
|
| Signal Transduction | 42 | 2019 | 1671 | 1.550 |
Why?
|
| Uterine Neoplasms | 8 | 2016 | 60 | 1.540 |
Why?
|
| Carcinoma, Endometrioid | 12 | 2019 | 38 | 1.540 |
Why?
|
| Neoplasms | 13 | 2023 | 1325 | 1.490 |
Why?
|
| Carcinoma | 12 | 2012 | 138 | 1.460 |
Why?
|
| Piperazines | 7 | 2019 | 118 | 1.400 |
Why?
|
| Genital Neoplasms, Female | 7 | 2016 | 48 | 1.380 |
Why?
|
| Adult | 82 | 2025 | 14161 | 1.370 |
Why?
|
| Clinical Trials as Topic | 12 | 2024 | 467 | 1.300 |
Why?
|
| Cell Line, Tumor | 50 | 2021 | 1470 | 1.290 |
Why?
|
| Neoplasm Proteins | 13 | 2017 | 334 | 1.290 |
Why?
|
| Disease-Free Survival | 23 | 2023 | 460 | 1.290 |
Why?
|
| Transcriptome | 11 | 2019 | 370 | 1.270 |
Why?
|
| Aged, 80 and over | 47 | 2024 | 3392 | 1.270 |
Why?
|
| Carcinoma, Papillary | 5 | 2012 | 51 | 1.220 |
Why?
|
| Breast Neoplasms | 16 | 2022 | 1212 | 1.220 |
Why?
|
| Immunohistochemistry | 36 | 2022 | 979 | 1.180 |
Why?
|
| Phthalazines | 6 | 2019 | 20 | 1.170 |
Why?
|
| Genomics | 6 | 2021 | 268 | 1.170 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2017 | 528 | 1.120 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2020 | 74 | 1.090 |
Why?
|
| Recombinant Fusion Proteins | 10 | 2024 | 177 | 1.090 |
Why?
|
| Cell Transformation, Neoplastic | 19 | 2011 | 184 | 1.050 |
Why?
|
| Databases, Genetic | 7 | 2021 | 83 | 1.050 |
Why?
|
| Animals | 96 | 2024 | 13505 | 1.040 |
Why?
|
| Carcinosarcoma | 6 | 2016 | 18 | 1.040 |
Why?
|
| Lung Neoplasms | 29 | 2017 | 636 | 1.000 |
Why?
|
| Platinum | 4 | 2022 | 11 | 0.970 |
Why?
|
| Mice | 65 | 2024 | 5949 | 0.950 |
Why?
|
| Transcription Factors | 22 | 2018 | 566 | 0.950 |
Why?
|
| Cell Cycle Proteins | 13 | 2012 | 169 | 0.930 |
Why?
|
| Apoptosis | 30 | 2021 | 1119 | 0.910 |
Why?
|
| Phosphatidylinositol 3-Kinases | 9 | 2019 | 151 | 0.910 |
Why?
|
| RNA, Messenger | 36 | 2015 | 1132 | 0.890 |
Why?
|
| Cisplatin | 16 | 2023 | 285 | 0.870 |
Why?
|
| DNA, Neoplasm | 18 | 2017 | 146 | 0.860 |
Why?
|
| Proto-Oncogene Proteins c-akt | 9 | 2024 | 169 | 0.830 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2016 | 221 | 0.820 |
Why?
|
| Genes, jun | 17 | 2007 | 21 | 0.820 |
Why?
|
| Germ-Line Mutation | 5 | 2019 | 66 | 0.810 |
Why?
|
| Cell Movement | 17 | 2021 | 268 | 0.790 |
Why?
|
| Adenocarcinoma, Mucinous | 8 | 2014 | 20 | 0.790 |
Why?
|
| Neoplasm Invasiveness | 19 | 2016 | 278 | 0.780 |
Why?
|
| Neutropenia | 1 | 2023 | 115 | 0.780 |
Why?
|
| Niacinamide | 3 | 2019 | 23 | 0.770 |
Why?
|
| Nuclear Proteins | 11 | 2018 | 245 | 0.760 |
Why?
|
| Pyridines | 2 | 2015 | 132 | 0.760 |
Why?
|
| DNA-Binding Proteins | 19 | 2018 | 422 | 0.740 |
Why?
|
| Optical Imaging | 2 | 2019 | 26 | 0.740 |
Why?
|
| Proto-Oncogene Proteins | 14 | 2012 | 151 | 0.730 |
Why?
|
| Contrast Media | 3 | 2019 | 193 | 0.720 |
Why?
|
| Neoplasm Grading | 15 | 2021 | 126 | 0.720 |
Why?
|
| Nanotubes, Carbon | 2 | 2019 | 69 | 0.710 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2016 | 17 | 0.700 |
Why?
|
| Treatment Outcome | 27 | 2023 | 5422 | 0.700 |
Why?
|
| Genes, Tumor Suppressor | 15 | 2015 | 74 | 0.690 |
Why?
|
| Oncogenes | 16 | 2013 | 60 | 0.690 |
Why?
|
| Tumor Cells, Cultured | 39 | 2021 | 460 | 0.690 |
Why?
|
| Survival Rate | 19 | 2020 | 945 | 0.670 |
Why?
|
| Genes, ras | 11 | 2001 | 43 | 0.660 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2017 | 595 | 0.660 |
Why?
|
| Tumor Suppressor Proteins | 9 | 2016 | 130 | 0.650 |
Why?
|
| Gene Amplification | 14 | 2013 | 58 | 0.650 |
Why?
|
| Mitogen-Activated Protein Kinases | 17 | 2009 | 155 | 0.650 |
Why?
|
| Quality of Life | 3 | 2023 | 879 | 0.640 |
Why?
|
| Tumor Microenvironment | 8 | 2024 | 256 | 0.640 |
Why?
|
| Ovary | 9 | 2019 | 107 | 0.630 |
Why?
|
| Transfection | 31 | 2020 | 357 | 0.630 |
Why?
|
| ras Proteins | 9 | 2012 | 64 | 0.630 |
Why?
|
| Disease Progression | 16 | 2022 | 871 | 0.620 |
Why?
|
| Paraffin Embedding | 6 | 2020 | 52 | 0.620 |
Why?
|
| Tablets | 2 | 2018 | 31 | 0.610 |
Why?
|
| Adenocarcinoma | 10 | 2021 | 405 | 0.610 |
Why?
|
| Contractile Proteins | 3 | 2019 | 5 | 0.610 |
Why?
|
| Proteomics | 3 | 2024 | 329 | 0.610 |
Why?
|
| Antibodies, Monoclonal | 8 | 2023 | 481 | 0.600 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2020 | 483 | 0.600 |
Why?
|
| Transforming Growth Factor beta | 5 | 2020 | 138 | 0.600 |
Why?
|
| BRCA1 Protein | 9 | 2024 | 34 | 0.600 |
Why?
|
| Cell Proliferation | 26 | 2021 | 1023 | 0.600 |
Why?
|
| Cell Cycle | 13 | 2012 | 230 | 0.590 |
Why?
|
| Polymorphism, Single Nucleotide | 15 | 2019 | 505 | 0.590 |
Why?
|
| Gene Expression | 20 | 2016 | 618 | 0.580 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2015 | 87 | 0.580 |
Why?
|
| Gene Expression Regulation | 19 | 2014 | 990 | 0.570 |
Why?
|
| NF-kappa B | 9 | 2013 | 322 | 0.570 |
Why?
|
| Up-Regulation | 15 | 2017 | 454 | 0.570 |
Why?
|
| Glycoproteins | 3 | 2017 | 122 | 0.560 |
Why?
|
| Transcription, Genetic | 19 | 2009 | 378 | 0.560 |
Why?
|
| Transcriptional Activation | 14 | 2009 | 122 | 0.550 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 22 | 2015 | 582 | 0.550 |
Why?
|
| Ascitic Fluid | 1 | 2017 | 13 | 0.550 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2017 | 220 | 0.550 |
Why?
|
| Proportional Hazards Models | 9 | 2021 | 443 | 0.550 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2015 | 134 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2010 | 33 | 0.540 |
Why?
|
| Neoplastic Stem Cells | 4 | 2018 | 99 | 0.530 |
Why?
|
| Clone Cells | 4 | 2016 | 77 | 0.530 |
Why?
|
| Survival Analysis | 17 | 2023 | 673 | 0.530 |
Why?
|
| MicroRNAs | 9 | 2017 | 387 | 0.530 |
Why?
|
| Promoter Regions, Genetic | 16 | 2013 | 467 | 0.530 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2019 | 227 | 0.520 |
Why?
|
| Tissue Fixation | 2 | 2020 | 36 | 0.520 |
Why?
|
| Proto-Oncogene Proteins c-fos | 16 | 2009 | 60 | 0.500 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 7 | 2011 | 17 | 0.500 |
Why?
|
| Young Adult | 14 | 2024 | 4329 | 0.500 |
Why?
|
| Mice, Nude | 14 | 2019 | 265 | 0.500 |
Why?
|
| Epithelial Cells | 10 | 2013 | 215 | 0.490 |
Why?
|
| Oxazines | 1 | 2015 | 4 | 0.490 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 44 | 0.490 |
Why?
|
| Acid Anhydride Hydrolases | 3 | 2001 | 14 | 0.490 |
Why?
|
| Cluster Analysis | 9 | 2015 | 233 | 0.490 |
Why?
|
| Microtubules | 1 | 2015 | 39 | 0.480 |
Why?
|
| Formaldehyde | 1 | 2015 | 51 | 0.470 |
Why?
|
| Genome-Wide Association Study | 7 | 2017 | 186 | 0.470 |
Why?
|
| Polymerase Chain Reaction | 12 | 2012 | 461 | 0.470 |
Why?
|
| Diarrhea | 5 | 2019 | 95 | 0.460 |
Why?
|
| Nanotechnology | 1 | 2015 | 41 | 0.460 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2023 | 105 | 0.460 |
Why?
|
| Prostatic Neoplasms | 4 | 2015 | 398 | 0.460 |
Why?
|
| Fatigue | 5 | 2019 | 125 | 0.460 |
Why?
|
| Precancerous Conditions | 5 | 2009 | 85 | 0.460 |
Why?
|
| Quinoxalines | 3 | 2021 | 26 | 0.460 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 182 | 0.450 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 253 | 0.440 |
Why?
|
| Predictive Value of Tests | 9 | 2014 | 944 | 0.440 |
Why?
|
| Nausea | 4 | 2018 | 46 | 0.430 |
Why?
|
| Piperidines | 3 | 2019 | 97 | 0.430 |
Why?
|
| Neoplasm Metastasis | 7 | 2024 | 243 | 0.430 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 5 | 2019 | 17 | 0.430 |
Why?
|
| Platinum Compounds | 5 | 2019 | 11 | 0.430 |
Why?
|
| Microdissection | 3 | 2019 | 19 | 0.420 |
Why?
|
| Blotting, Western | 16 | 2017 | 590 | 0.420 |
Why?
|
| Proteome | 1 | 2015 | 171 | 0.420 |
Why?
|
| Sarcoma | 1 | 2014 | 72 | 0.420 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 46 | 0.420 |
Why?
|
| Rats | 23 | 2013 | 3220 | 0.420 |
Why?
|
| Pyrimidines | 2 | 2016 | 199 | 0.420 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2023 | 183 | 0.410 |
Why?
|
| Antigens, CD | 3 | 2010 | 218 | 0.410 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2017 | 170 | 0.410 |
Why?
|
| Angioplasty, Balloon | 4 | 2002 | 68 | 0.410 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2010 | 15 | 0.410 |
Why?
|
| Phosphoproteins | 7 | 2021 | 119 | 0.410 |
Why?
|
| Drug Administration Schedule | 13 | 2020 | 374 | 0.400 |
Why?
|
| Genome, Human | 7 | 2019 | 121 | 0.400 |
Why?
|
| Microtubule-Associated Proteins | 4 | 2001 | 65 | 0.400 |
Why?
|
| Genes, erbB-2 | 2 | 2009 | 8 | 0.390 |
Why?
|
| Cell Division | 17 | 2004 | 291 | 0.390 |
Why?
|
| Genes, myc | 4 | 2009 | 39 | 0.390 |
Why?
|
| beta Karyopherins | 3 | 2021 | 4 | 0.390 |
Why?
|
| Base Sequence | 22 | 2010 | 640 | 0.380 |
Why?
|
| Stromal Cells | 6 | 2019 | 79 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2020 | 1378 | 0.380 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2022 | 263 | 0.380 |
Why?
|
| RNA, Small Interfering | 15 | 2017 | 213 | 0.370 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 4 | 2018 | 7 | 0.370 |
Why?
|
| Drug Delivery Systems | 2 | 2014 | 154 | 0.370 |
Why?
|
| Cell Differentiation | 10 | 2004 | 665 | 0.370 |
Why?
|
| Pancreatic Neoplasms | 3 | 2019 | 216 | 0.370 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 2279 | 0.370 |
Why?
|
| Cell Adhesion | 8 | 2015 | 163 | 0.370 |
Why?
|
| Thrombocytopenia | 3 | 2022 | 89 | 0.360 |
Why?
|
| Maximum Tolerated Dose | 4 | 2019 | 39 | 0.350 |
Why?
|
| Genes, p53 | 5 | 2001 | 52 | 0.350 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 10 | 0.350 |
Why?
|
| Leiomyosarcoma | 2 | 2003 | 21 | 0.350 |
Why?
|
| Pyrroles | 3 | 2021 | 71 | 0.350 |
Why?
|
| Cystadenoma, Serous | 2 | 2016 | 5 | 0.350 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2010 | 4 | 0.350 |
Why?
|
| Medical Oncology | 2 | 2019 | 104 | 0.340 |
Why?
|
| Morpholines | 5 | 2018 | 66 | 0.340 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 16 | 2010 | 72 | 0.340 |
Why?
|
| Tissue Array Analysis | 8 | 2016 | 46 | 0.340 |
Why?
|
| Research | 2 | 2008 | 107 | 0.340 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2010 | 19 | 0.340 |
Why?
|
| Recombinational DNA Repair | 2 | 2021 | 10 | 0.330 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2007 | 56 | 0.330 |
Why?
|
| DNA Mutational Analysis | 9 | 2016 | 180 | 0.330 |
Why?
|
| Fibroblasts | 8 | 2013 | 355 | 0.320 |
Why?
|
| BRCA2 Protein | 6 | 2024 | 19 | 0.320 |
Why?
|
| Proteins | 4 | 2023 | 348 | 0.320 |
Why?
|
| Cell Line | 20 | 2013 | 1030 | 0.320 |
Why?
|
| Molecular Sequence Data | 20 | 2007 | 778 | 0.310 |
Why?
|
| Indazoles | 2 | 2019 | 47 | 0.310 |
Why?
|
| Genome | 2 | 2006 | 62 | 0.310 |
Why?
|
| Doxorubicin | 5 | 2019 | 241 | 0.310 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 10 | 2012 | 34 | 0.310 |
Why?
|
| Prospective Studies | 11 | 2021 | 2481 | 0.300 |
Why?
|
| Double-Blind Method | 6 | 2021 | 713 | 0.300 |
Why?
|
| Genes, fos | 13 | 2007 | 28 | 0.300 |
Why?
|
| RNA, Neoplasm | 9 | 2015 | 45 | 0.300 |
Why?
|
| Camptothecin | 2 | 2021 | 15 | 0.300 |
Why?
|
| Cyclodextrins | 2 | 2021 | 18 | 0.300 |
Why?
|
| Osteosarcoma | 1 | 2008 | 44 | 0.300 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2009 | 52 | 0.300 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2019 | 124 | 0.290 |
Why?
|
| RNA Interference | 6 | 2017 | 181 | 0.290 |
Why?
|
| Nanoparticles | 4 | 2017 | 160 | 0.290 |
Why?
|
| Models, Biological | 6 | 2012 | 735 | 0.290 |
Why?
|
| Topotecan | 3 | 2023 | 17 | 0.280 |
Why?
|
| Benzimidazoles | 2 | 2021 | 49 | 0.280 |
Why?
|
| Tumor Burden | 5 | 2015 | 136 | 0.280 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2007 | 1 | 0.280 |
Why?
|
| Bacteriophage M13 | 2 | 2019 | 2 | 0.280 |
Why?
|
| Reproducibility of Results | 7 | 2018 | 1229 | 0.270 |
Why?
|
| Disease Models, Animal | 6 | 2024 | 1478 | 0.270 |
Why?
|
| Pilot Projects | 2 | 2022 | 721 | 0.270 |
Why?
|
| Societies, Medical | 1 | 2008 | 200 | 0.270 |
Why?
|
| Maintenance Chemotherapy | 4 | 2021 | 51 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2004 | 332 | 0.270 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 184 | 0.260 |
Why?
|
| Vision Disorders | 2 | 2017 | 60 | 0.260 |
Why?
|
| Binding Sites | 11 | 2013 | 377 | 0.260 |
Why?
|
| Cyclin A | 2 | 2008 | 6 | 0.260 |
Why?
|
| Sulfonamides | 2 | 2019 | 133 | 0.260 |
Why?
|
| Proto-Oncogenes | 8 | 2003 | 27 | 0.260 |
Why?
|
| Receptors, Estrogen | 6 | 2013 | 131 | 0.250 |
Why?
|
| Membrane Proteins | 5 | 2019 | 335 | 0.250 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2020 | 399 | 0.250 |
Why?
|
| Mice, SCID | 5 | 2021 | 182 | 0.250 |
Why?
|
| Genes, Dominant | 6 | 2005 | 21 | 0.250 |
Why?
|
| MAP Kinase Kinase Kinases | 3 | 2019 | 19 | 0.240 |
Why?
|
| CA-125 Antigen | 6 | 2021 | 16 | 0.240 |
Why?
|
| DNA | 12 | 2008 | 549 | 0.240 |
Why?
|
| ras-GRF1 | 1 | 2005 | 1 | 0.240 |
Why?
|
| Recurrence | 5 | 2023 | 672 | 0.240 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2014 | 202 | 0.240 |
Why?
|
| Cells, Cultured | 15 | 2009 | 1567 | 0.240 |
Why?
|
| Genetic Loci | 2 | 2017 | 49 | 0.240 |
Why?
|
| Blotting, Northern | 9 | 2010 | 106 | 0.240 |
Why?
|
| Protein Biosynthesis | 3 | 2001 | 258 | 0.230 |
Why?
|
| Microvessels | 3 | 2017 | 31 | 0.230 |
Why?
|
| Tetradecanoylphorbol Acetate | 8 | 1996 | 46 | 0.230 |
Why?
|
| Renal Artery Obstruction | 2 | 2002 | 21 | 0.230 |
Why?
|
| DNA Copy Number Variations | 2 | 2017 | 117 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2023 | 182 | 0.230 |
Why?
|
| Interleukin-6 | 2 | 2020 | 278 | 0.230 |
Why?
|
| HMGA1a Protein | 1 | 2004 | 1 | 0.230 |
Why?
|
| Mutation Rate | 2 | 2016 | 36 | 0.220 |
Why?
|
| Neutrophil Activation | 1 | 2024 | 13 | 0.220 |
Why?
|
| Iliac Artery | 2 | 2001 | 31 | 0.220 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 6 | 1999 | 34 | 0.220 |
Why?
|
| Benzamides | 2 | 2017 | 50 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 7 | 2011 | 68 | 0.220 |
Why?
|
| Cyclin D1 | 2 | 2002 | 57 | 0.220 |
Why?
|
| Organoplatinum Compounds | 3 | 2020 | 14 | 0.220 |
Why?
|
| Biological Therapy | 1 | 2003 | 16 | 0.220 |
Why?
|
| Stents | 3 | 2002 | 351 | 0.210 |
Why?
|
| Cell Lineage | 2 | 2018 | 85 | 0.210 |
Why?
|
| Point Mutation | 7 | 2012 | 67 | 0.210 |
Why?
|
| Luciferases | 5 | 2019 | 48 | 0.210 |
Why?
|
| Microtubule Proteins | 1 | 2003 | 2 | 0.210 |
Why?
|
| United States | 12 | 2020 | 5192 | 0.210 |
Why?
|
| Neoplasm Transplantation | 6 | 2013 | 87 | 0.210 |
Why?
|
| Down-Regulation | 10 | 2011 | 346 | 0.210 |
Why?
|
| Quinazolines | 3 | 2019 | 34 | 0.210 |
Why?
|
| Receptor, erbB-2 | 2 | 2022 | 80 | 0.210 |
Why?
|
| Cohort Studies | 6 | 2019 | 1542 | 0.210 |
Why?
|
| Epithelium | 5 | 2011 | 65 | 0.210 |
Why?
|
| Drug Synergism | 3 | 2021 | 150 | 0.210 |
Why?
|
| Fenretinide | 2 | 2004 | 5 | 0.200 |
Why?
|
| Histone Deacetylases | 1 | 2003 | 51 | 0.200 |
Why?
|
| Neutrophils | 1 | 2024 | 147 | 0.200 |
Why?
|
| Genes, Reporter | 6 | 2006 | 88 | 0.200 |
Why?
|
| Protein Binding | 10 | 2016 | 667 | 0.200 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2003 | 153 | 0.200 |
Why?
|
| Cell Nucleus | 6 | 2016 | 187 | 0.200 |
Why?
|
| Tamoxifen | 4 | 2016 | 60 | 0.200 |
Why?
|
| Molecular Biology | 4 | 2016 | 27 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-myc | 7 | 1996 | 53 | 0.200 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2002 | 5 | 0.200 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2002 | 15 | 0.200 |
Why?
|
| Apoptosis Regulatory Proteins | 5 | 2023 | 86 | 0.200 |
Why?
|
| DNA Primers | 7 | 2010 | 208 | 0.200 |
Why?
|
| Cell Survival | 7 | 2016 | 612 | 0.200 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 18 | 0.200 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2024 | 291 | 0.190 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2002 | 2 | 0.190 |
Why?
|
| Versicans | 2 | 2013 | 10 | 0.190 |
Why?
|
| Fear | 1 | 2023 | 82 | 0.190 |
Why?
|
| Stathmin | 2 | 2017 | 2 | 0.190 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2021 | 1 | 0.190 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2021 | 7 | 0.190 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 80 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 5 | 2013 | 121 | 0.190 |
Why?
|
| Cytokines | 3 | 2013 | 623 | 0.190 |
Why?
|
| GTP-Binding Proteins | 2 | 1999 | 85 | 0.190 |
Why?
|
| Disease Management | 2 | 2020 | 188 | 0.190 |
Why?
|
| Monitoring, Immunologic | 2 | 2011 | 4 | 0.190 |
Why?
|
| Cell Death | 4 | 2011 | 177 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 13 | 0.190 |
Why?
|
| X Chromosome | 1 | 2001 | 13 | 0.190 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 19 | 0.190 |
Why?
|
| Peptides | 6 | 2017 | 223 | 0.190 |
Why?
|
| Male | 24 | 2018 | 26761 | 0.180 |
Why?
|
| Fibrosis | 2 | 2019 | 196 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2017 | 111 | 0.180 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 406 | 0.180 |
Why?
|
| Intermittent Claudication | 1 | 2001 | 13 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 5 | 2017 | 153 | 0.180 |
Why?
|
| Diabetic Angiopathies | 1 | 2001 | 23 | 0.180 |
Why?
|
| Drug Design | 3 | 2014 | 120 | 0.180 |
Why?
|
| Genotype | 8 | 2017 | 566 | 0.180 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 34 | 0.180 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 21 | 0.180 |
Why?
|
| Immunotherapy | 2 | 2020 | 244 | 0.180 |
Why?
|
| Subcutaneous Fat | 1 | 2021 | 19 | 0.180 |
Why?
|
| Somatomedins | 1 | 2021 | 30 | 0.180 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2019 | 23 | 0.180 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2021 | 39 | 0.180 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2011 | 59 | 0.180 |
Why?
|
| Iliac Aneurysm | 1 | 2000 | 10 | 0.170 |
Why?
|
| Kidney Neoplasms | 2 | 2017 | 182 | 0.170 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2021 | 42 | 0.170 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2020 | 33 | 0.170 |
Why?
|
| Ascites | 3 | 2017 | 32 | 0.170 |
Why?
|
| Survivors | 1 | 2021 | 120 | 0.170 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 23 | 0.170 |
Why?
|
| Macrophages | 4 | 2000 | 379 | 0.170 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2000 | 14 | 0.170 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 220 | 0.170 |
Why?
|
| Genes, BRCA1 | 3 | 2021 | 19 | 0.170 |
Why?
|
| Flow Cytometry | 3 | 2019 | 478 | 0.170 |
Why?
|
| Time Factors | 7 | 2019 | 2968 | 0.170 |
Why?
|
| Receptors, Retinoic Acid | 3 | 2004 | 22 | 0.170 |
Why?
|
| Peptide Fragments | 7 | 2011 | 203 | 0.170 |
Why?
|
| Histological Techniques | 1 | 2020 | 9 | 0.170 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2019 | 6 | 0.170 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 5 | 0.170 |
Why?
|
| Retreatment | 2 | 2016 | 58 | 0.170 |
Why?
|
| Cytoskeletal Proteins | 2 | 2017 | 48 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2010 | 47 | 0.170 |
Why?
|
| Pyridones | 2 | 2019 | 36 | 0.170 |
Why?
|
| Specimen Handling | 1 | 2020 | 56 | 0.160 |
Why?
|
| p21-Activated Kinases | 2 | 2013 | 3 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 173 | 0.160 |
Why?
|
| Indoles | 3 | 2011 | 278 | 0.160 |
Why?
|
| Osteonectin | 1 | 2019 | 10 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 891 | 0.160 |
Why?
|
| Genetic Markers | 4 | 2012 | 109 | 0.160 |
Why?
|
| Case-Control Studies | 8 | 2019 | 1201 | 0.160 |
Why?
|
| Doxycycline | 4 | 2013 | 33 | 0.160 |
Why?
|
| Retinoblastoma Protein | 6 | 2002 | 19 | 0.160 |
Why?
|
| Retrospective Studies | 10 | 2024 | 6607 | 0.160 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 1 | 2019 | 4 | 0.160 |
Why?
|
| U937 Cells | 2 | 2000 | 15 | 0.160 |
Why?
|
| Carrier Proteins | 5 | 2012 | 313 | 0.160 |
Why?
|
| LIM Domain Proteins | 2 | 2017 | 8 | 0.160 |
Why?
|
| MAP Kinase Kinase 4 | 5 | 2004 | 29 | 0.150 |
Why?
|
| Early Growth Response Protein 1 | 2 | 2009 | 34 | 0.150 |
Why?
|
| Thiazoles | 1 | 2019 | 55 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2017 | 136 | 0.150 |
Why?
|
| Germ Cells | 1 | 2018 | 14 | 0.150 |
Why?
|
| Corneal Diseases | 1 | 2018 | 15 | 0.150 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2019 | 53 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2018 | 20 | 0.150 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2016 | 54 | 0.150 |
Why?
|
| Monomeric GTP-Binding Proteins | 2 | 2009 | 9 | 0.150 |
Why?
|
| Insulin | 1 | 2021 | 479 | 0.150 |
Why?
|
| Green Fluorescent Proteins | 3 | 2019 | 93 | 0.150 |
Why?
|
| Angiopoietin-2 | 1 | 2018 | 15 | 0.150 |
Why?
|
| Phosphorylation | 11 | 2017 | 528 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2018 | 72 | 0.150 |
Why?
|
| Gene Dosage | 3 | 2011 | 78 | 0.150 |
Why?
|
| Reactive Oxygen Species | 3 | 2021 | 421 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 78 | 0.150 |
Why?
|
| Microarray Analysis | 2 | 2016 | 71 | 0.150 |
Why?
|
| Bufanolides | 1 | 1998 | 1 | 0.150 |
Why?
|
| 3T3 Cells | 8 | 2000 | 58 | 0.150 |
Why?
|
| Genes, BRCA2 | 2 | 2021 | 13 | 0.150 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 18 | 0.150 |
Why?
|
| Cyclins | 6 | 2001 | 38 | 0.150 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1999 | 133 | 0.140 |
Why?
|
| Forkhead Transcription Factors | 3 | 2013 | 116 | 0.140 |
Why?
|
| Mitosis | 3 | 2012 | 88 | 0.140 |
Why?
|
| Risk Factors | 10 | 2017 | 3889 | 0.140 |
Why?
|
| Enzyme Activation | 11 | 2008 | 270 | 0.140 |
Why?
|
| Incidence | 2 | 2018 | 1062 | 0.140 |
Why?
|
| Receptor, Notch2 | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cell Line, Transformed | 5 | 2013 | 74 | 0.140 |
Why?
|
| Polycomb Repressive Complex 2 | 3 | 2012 | 48 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2015 | 80 | 0.140 |
Why?
|
| Chromatin Immunoprecipitation | 5 | 2011 | 48 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 80 | 0.140 |
Why?
|
| Computational Biology | 2 | 2018 | 212 | 0.140 |
Why?
|
| Hypophosphatemia | 1 | 2017 | 5 | 0.140 |
Why?
|
| Data Mining | 2 | 2018 | 44 | 0.140 |
Why?
|
| Oligonucleotides, Antisense | 4 | 2005 | 30 | 0.140 |
Why?
|
| Infusions, Intravenous | 4 | 2019 | 220 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2016 | 55 | 0.140 |
Why?
|
| Leiomyoma | 1 | 1997 | 23 | 0.140 |
Why?
|
| Keratitis | 1 | 2017 | 12 | 0.140 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2017 | 53 | 0.140 |
Why?
|
| Aminopyridines | 1 | 2017 | 15 | 0.140 |
Why?
|
| Epothilones | 1 | 2016 | 1 | 0.130 |
Why?
|
| Protein Kinases | 5 | 1998 | 72 | 0.130 |
Why?
|
| Catheters, Indwelling | 1 | 2017 | 58 | 0.130 |
Why?
|
| Phenotype | 7 | 2018 | 789 | 0.130 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 3 | 2014 | 34 | 0.130 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2016 | 25 | 0.130 |
Why?
|
| Esophageal Neoplasms | 2 | 2009 | 111 | 0.130 |
Why?
|
| Homologous Recombination | 1 | 2017 | 41 | 0.130 |
Why?
|
| Aminopterin | 1 | 2016 | 2 | 0.130 |
Why?
|
| Glucocorticoids | 1 | 2018 | 235 | 0.130 |
Why?
|
| Genetic Therapy | 2 | 2015 | 121 | 0.130 |
Why?
|
| Cyclin E | 3 | 2010 | 4 | 0.130 |
Why?
|
| Antiemetics | 1 | 2016 | 32 | 0.130 |
Why?
|
| Retinoblastoma | 2 | 1995 | 15 | 0.130 |
Why?
|
| Actins | 2 | 2014 | 115 | 0.130 |
Why?
|
| Megestrol Acetate | 1 | 2016 | 17 | 0.130 |
Why?
|
| Triazines | 1 | 2016 | 26 | 0.130 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 39 | 0.130 |
Why?
|
| Tissue Distribution | 1 | 2016 | 171 | 0.130 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2015 | 8 | 0.130 |
Why?
|
| Hypotension | 1 | 2016 | 62 | 0.130 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 28 | 0.130 |
Why?
|
| Mosaicism | 1 | 2016 | 17 | 0.130 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 133 | 0.130 |
Why?
|
| Protein Isoforms | 1 | 2016 | 123 | 0.130 |
Why?
|
| Enzyme Inhibitors | 5 | 2003 | 372 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 3 | 2017 | 86 | 0.130 |
Why?
|
| Benzodiazepines | 1 | 2016 | 71 | 0.120 |
Why?
|
| Vomiting | 1 | 2016 | 73 | 0.120 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2015 | 4 | 0.120 |
Why?
|
| Sirolimus | 1 | 2016 | 65 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 123 | 0.120 |
Why?
|
| Interferon-gamma | 3 | 2024 | 180 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 149 | 0.120 |
Why?
|
| Gene Library | 1 | 2015 | 44 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 48 | 0.120 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1994 | 1 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2008 | 71 | 0.120 |
Why?
|
| Early Detection of Cancer | 3 | 2017 | 189 | 0.120 |
Why?
|
| Troponin C | 1 | 2014 | 2 | 0.120 |
Why?
|
| Cytoplasm | 3 | 2005 | 94 | 0.120 |
Why?
|
| Neoplasm, Residual | 3 | 2017 | 173 | 0.120 |
Why?
|
| Chemokine CXCL12 | 2 | 2013 | 32 | 0.120 |
Why?
|
| Oncogene Proteins | 3 | 2011 | 19 | 0.120 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2014 | 17 | 0.120 |
Why?
|
| Papillomaviridae | 3 | 2021 | 105 | 0.120 |
Why?
|
| Dependovirus | 1 | 2015 | 103 | 0.110 |
Why?
|
| Heat-Shock Proteins | 3 | 2012 | 103 | 0.110 |
Why?
|
| Cell Transformation, Viral | 3 | 2000 | 25 | 0.110 |
Why?
|
| Carcinoma, Small Cell | 7 | 1996 | 26 | 0.110 |
Why?
|
| Genes, Neoplasm | 2 | 2011 | 31 | 0.110 |
Why?
|
| Receptors, CXCR4 | 2 | 2011 | 29 | 0.110 |
Why?
|
| Recombinant Proteins | 4 | 2009 | 483 | 0.110 |
Why?
|
| Hormones | 1 | 2014 | 59 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 3 | 2013 | 35 | 0.110 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 2 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 4 | 2013 | 137 | 0.110 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 2013 | 3 | 0.110 |
Why?
|
| Gene Silencing | 4 | 2017 | 118 | 0.110 |
Why?
|
| Adenosylmethionine Decarboxylase | 2 | 2006 | 3 | 0.110 |
Why?
|
| Diffusion of Innovation | 1 | 2014 | 47 | 0.110 |
Why?
|
| Loss of Heterozygosity | 3 | 2021 | 78 | 0.110 |
Why?
|
| Structure-Activity Relationship | 5 | 2017 | 404 | 0.110 |
Why?
|
| Age Factors | 2 | 2016 | 1132 | 0.110 |
Why?
|
| Mutagenesis, Site-Directed | 5 | 2009 | 95 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 35 | 0.110 |
Why?
|
| Necrosis | 2 | 2011 | 176 | 0.110 |
Why?
|
| Growth Substances | 7 | 1996 | 21 | 0.100 |
Why?
|
| Gases | 1 | 2013 | 9 | 0.100 |
Why?
|
| Molecular Sequence Annotation | 1 | 2013 | 28 | 0.100 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2013 | 1 | 0.100 |
Why?
|
| GPI-Linked Proteins | 2 | 2010 | 32 | 0.100 |
Why?
|
| Nitrogen Isotopes | 1 | 2013 | 38 | 0.100 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2012 | 3 | 0.100 |
Why?
|
| Measles virus | 3 | 1981 | 8 | 0.100 |
Why?
|
| Fallopian Tubes | 3 | 2023 | 23 | 0.100 |
Why?
|
| Quantitative Trait Loci | 1 | 2013 | 50 | 0.100 |
Why?
|
| Rats, Inbred F344 | 3 | 2003 | 197 | 0.100 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1994 | 139 | 0.100 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2015 | 29 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 84 | 0.100 |
Why?
|
| Environmental Monitoring | 1 | 2013 | 74 | 0.100 |
Why?
|
| Globins | 2 | 2009 | 14 | 0.100 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 1 | 2012 | 1 | 0.100 |
Why?
|
| Endonucleases | 1 | 2012 | 14 | 0.100 |
Why?
|
| Ribonuclease III | 2 | 2008 | 14 | 0.100 |
Why?
|
| Interleukin-1alpha | 1 | 2012 | 10 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2012 | 11 | 0.100 |
Why?
|
| Dipeptides | 1 | 2012 | 21 | 0.100 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 25 | 0.090 |
Why?
|
| Hedgehog Proteins | 1 | 2011 | 34 | 0.090 |
Why?
|
| Research Design | 1 | 2014 | 359 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2009 | 105 | 0.090 |
Why?
|
| Immunocompetence | 1 | 2011 | 19 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2012 | 114 | 0.090 |
Why?
|
| Rabbits | 3 | 2018 | 375 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 83 | 0.090 |
Why?
|
| Liver Neoplasms | 3 | 2013 | 333 | 0.090 |
Why?
|
| Wnt Proteins | 1 | 2011 | 100 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2010 | 17 | 0.090 |
Why?
|
| Respiratory Mucosa | 1 | 2010 | 10 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2010 | 8 | 0.090 |
Why?
|
| Vinblastine | 2 | 2020 | 23 | 0.090 |
Why?
|
| Computer Simulation | 3 | 2022 | 290 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 85 | 0.090 |
Why?
|
| Endometriosis | 1 | 2010 | 15 | 0.090 |
Why?
|
| Genomic Instability | 2 | 2021 | 89 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2010 | 25 | 0.090 |
Why?
|
| Hong Kong | 2 | 2009 | 7 | 0.090 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 244 | 0.090 |
Why?
|
| Glucose | 2 | 2011 | 355 | 0.090 |
Why?
|
| Mitochondria | 2 | 2024 | 430 | 0.090 |
Why?
|
| I-kappa B Kinase | 1 | 2010 | 20 | 0.080 |
Why?
|
| Oxidative Stress | 2 | 2013 | 807 | 0.080 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 122 | 0.080 |
Why?
|
| Elafin | 1 | 2010 | 2 | 0.080 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 55 | 0.080 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2001 | 79 | 0.080 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2010 | 10 | 0.080 |
Why?
|
| Cell Growth Processes | 4 | 2012 | 22 | 0.080 |
Why?
|
| Kinetics | 4 | 2013 | 626 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2012 | 69 | 0.080 |
Why?
|
| Patient Selection | 2 | 2014 | 259 | 0.080 |
Why?
|
| Lung | 2 | 2024 | 509 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2021 | 1327 | 0.080 |
Why?
|
| Chromosome Deletion | 5 | 2013 | 142 | 0.080 |
Why?
|
| Bronchioles | 1 | 2009 | 2 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 151 | 0.080 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2009 | 10 | 0.080 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 43 | 0.080 |
Why?
|
| Ceramides | 3 | 2003 | 34 | 0.080 |
Why?
|
| Chemokine CXCL2 | 1 | 2009 | 11 | 0.080 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2009 | 5 | 0.080 |
Why?
|
| NFATC Transcription Factors | 2 | 2007 | 23 | 0.080 |
Why?
|
| Pulmonary Alveoli | 1 | 2009 | 25 | 0.080 |
Why?
|
| Genes | 2 | 1988 | 31 | 0.080 |
Why?
|
| Karyopherins | 1 | 2009 | 6 | 0.080 |
Why?
|
| Apolipoprotein A-I | 1 | 2009 | 6 | 0.080 |
Why?
|
| Transferrin | 1 | 2009 | 12 | 0.080 |
Why?
|
| Models, Genetic | 2 | 2011 | 169 | 0.080 |
Why?
|
| Oxidation-Reduction | 2 | 2021 | 326 | 0.080 |
Why?
|
| Prealbumin | 1 | 2009 | 22 | 0.080 |
Why?
|
| HLA-D Antigens | 1 | 2008 | 4 | 0.080 |
Why?
|
| Organoids | 1 | 2009 | 39 | 0.080 |
Why?
|
| Exons | 3 | 2016 | 102 | 0.080 |
Why?
|
| Alleles | 3 | 2017 | 276 | 0.080 |
Why?
|
| Single-Cell Analysis | 2 | 2020 | 81 | 0.080 |
Why?
|
| Aspartate-Ammonia Ligase | 1 | 2008 | 1 | 0.080 |
Why?
|
| Endoribonucleases | 1 | 2008 | 17 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2009 | 67 | 0.080 |
Why?
|
| Asparaginase | 1 | 2008 | 4 | 0.080 |
Why?
|
| Neuropeptides | 3 | 1998 | 37 | 0.080 |
Why?
|
| Clusterin | 1 | 2008 | 8 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 61 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 171 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2008 | 66 | 0.080 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2008 | 34 | 0.080 |
Why?
|
| Receptors, Progesterone | 2 | 2013 | 66 | 0.070 |
Why?
|
| Response Elements | 2 | 2009 | 29 | 0.070 |
Why?
|
| Polyethylene Glycols | 2 | 2019 | 90 | 0.070 |
Why?
|
| Contact Inhibition | 2 | 2006 | 3 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2017 | 158 | 0.070 |
Why?
|
| Multigene Family | 2 | 2007 | 48 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2008 | 122 | 0.070 |
Why?
|
| Estrogen Antagonists | 2 | 1999 | 21 | 0.070 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2008 | 28 | 0.070 |
Why?
|
| Calcineurin | 1 | 2009 | 72 | 0.070 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2002 | 23 | 0.070 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2000 | 54 | 0.070 |
Why?
|
| Mollusca | 1 | 2007 | 1 | 0.070 |
Why?
|
| Hydroquinones | 1 | 2007 | 3 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 591 | 0.070 |
Why?
|
| Quinones | 1 | 2007 | 9 | 0.070 |
Why?
|
| Myocytes, Cardiac | 1 | 2009 | 129 | 0.070 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 1997 | 66 | 0.070 |
Why?
|
| Combined Modality Therapy | 4 | 2012 | 639 | 0.070 |
Why?
|
| RNA | 3 | 2002 | 168 | 0.070 |
Why?
|
| Jaundice | 1 | 1987 | 19 | 0.070 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2007 | 8 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 395 | 0.070 |
Why?
|
| Drug Discovery | 3 | 2016 | 93 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2007 | 17 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 47 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 4 | 2017 | 312 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2012 | 108 | 0.070 |
Why?
|
| ROC Curve | 2 | 2018 | 253 | 0.070 |
Why?
|
| Vitamin E | 2 | 1998 | 77 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 82 | 0.070 |
Why?
|
| Sequence Deletion | 4 | 1996 | 73 | 0.070 |
Why?
|
| Ornithine Decarboxylase | 2 | 2004 | 12 | 0.070 |
Why?
|
| Growth Inhibitors | 2 | 2007 | 26 | 0.070 |
Why?
|
| Intention to Treat Analysis | 2 | 2017 | 30 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1987 | 58 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 1987 | 49 | 0.070 |
Why?
|
| Protein Kinase C | 3 | 1998 | 68 | 0.070 |
Why?
|
| Erythropoiesis | 2 | 2004 | 18 | 0.070 |
Why?
|
| Eye Proteins | 1 | 2006 | 16 | 0.070 |
Why?
|
| Remission Induction | 2 | 2018 | 218 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2009 | 215 | 0.070 |
Why?
|
| NIH 3T3 Cells | 4 | 2009 | 51 | 0.070 |
Why?
|
| Cell Communication | 1 | 2006 | 71 | 0.060 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2006 | 36 | 0.060 |
Why?
|
| DNA Damage | 4 | 2021 | 305 | 0.060 |
Why?
|
| Thymosin | 1 | 2006 | 2 | 0.060 |
Why?
|
| Decision Trees | 1 | 2006 | 22 | 0.060 |
Why?
|
| G1 Phase | 2 | 2008 | 13 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2006 | 505 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 1046 | 0.060 |
Why?
|
| Liver | 3 | 2000 | 1156 | 0.060 |
Why?
|
| Retinoids | 2 | 2004 | 6 | 0.060 |
Why?
|
| DNA Repair | 2 | 2017 | 195 | 0.060 |
Why?
|
| Embryo, Mammalian | 4 | 2007 | 67 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2005 | 34 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 1678 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 2 | 2017 | 40 | 0.060 |
Why?
|
| Amino Acid Sequence | 7 | 2007 | 578 | 0.060 |
Why?
|
| Cyclin A2 | 1 | 2005 | 2 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 1165 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 181 | 0.060 |
Why?
|
| Image Enhancement | 1 | 2005 | 52 | 0.060 |
Why?
|
| Carotid Arteries | 1 | 2005 | 77 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2000 | 50 | 0.060 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2004 | 3 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2005 | 67 | 0.060 |
Why?
|
| Endometrium | 2 | 2019 | 43 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2009 | 111 | 0.060 |
Why?
|
| Staining and Labeling | 3 | 2008 | 97 | 0.060 |
Why?
|
| Cystadenocarcinoma, Mucinous | 1 | 2004 | 2 | 0.060 |
Why?
|
| Vascular Patency | 2 | 2002 | 82 | 0.060 |
Why?
|
| Creatinine | 2 | 2002 | 150 | 0.060 |
Why?
|
| Carcinogens | 3 | 1996 | 193 | 0.060 |
Why?
|
| Lasers | 1 | 2004 | 108 | 0.060 |
Why?
|
| Metalloendopeptidases | 1 | 2004 | 69 | 0.060 |
Why?
|
| Retinoid X Receptors | 1 | 2004 | 13 | 0.060 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2004 | 74 | 0.060 |
Why?
|
| Mouth Neoplasms | 1 | 2004 | 22 | 0.060 |
Why?
|
| Temperature | 3 | 2013 | 183 | 0.060 |
Why?
|
| Consensus | 2 | 2018 | 181 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 25 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 95 | 0.050 |
Why?
|
| Hypertension | 2 | 2019 | 565 | 0.050 |
Why?
|
| Pathology | 1 | 2004 | 38 | 0.050 |
Why?
|
| Urea | 1 | 2004 | 82 | 0.050 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2024 | 111 | 0.050 |
Why?
|
| Antibodies, Viral | 2 | 1981 | 109 | 0.050 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2004 | 51 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 166 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2000 | 62 | 0.050 |
Why?
|
| Hyperoxia | 1 | 2003 | 27 | 0.050 |
Why?
|
| Dexamethasone | 2 | 2016 | 438 | 0.050 |
Why?
|
| Genetic Vectors | 3 | 2003 | 128 | 0.050 |
Why?
|
| Women's Health | 1 | 2003 | 82 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2004 | 155 | 0.050 |
Why?
|
| Vimentin | 2 | 2000 | 32 | 0.050 |
Why?
|
| Receptors, Scavenger | 1 | 2023 | 29 | 0.050 |
Why?
|
| Transcription Factor RelA | 3 | 2010 | 32 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 94 | 0.050 |
Why?
|
| Taxoids | 2 | 2014 | 37 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 54 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2024 | 152 | 0.050 |
Why?
|
| Precipitin Tests | 3 | 1991 | 31 | 0.050 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2023 | 38 | 0.050 |
Why?
|
| Host-Pathogen Interactions | 1 | 2024 | 144 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 187 | 0.050 |
Why?
|
| Vasoactive Intestinal Peptide | 3 | 1998 | 20 | 0.050 |
Why?
|
| Protein Phosphatase 1 | 1 | 2002 | 7 | 0.050 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2002 | 10 | 0.050 |
Why?
|
| Causality | 1 | 2022 | 53 | 0.050 |
Why?
|
| Melanoma | 1 | 2006 | 288 | 0.050 |
Why?
|
| Gamma Rays | 1 | 2002 | 49 | 0.050 |
Why?
|
| Antigens, Viral | 2 | 1981 | 43 | 0.050 |
Why?
|
| Caspases | 4 | 2004 | 104 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2002 | 537 | 0.050 |
Why?
|
| Chromosome Mapping | 2 | 2013 | 154 | 0.050 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2021 | 13 | 0.050 |
Why?
|
| Allelic Imbalance | 1 | 2021 | 3 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 2 | 1992 | 32 | 0.050 |
Why?
|
| Wound Healing | 2 | 2017 | 219 | 0.050 |
Why?
|
| Research Support as Topic | 2 | 2014 | 44 | 0.050 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2001 | 6 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 46 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2013 | 87 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2021 | 64 | 0.050 |
Why?
|
| Ki-67 Antigen | 2 | 2012 | 58 | 0.050 |
Why?
|
| Endothelial Cells | 2 | 2017 | 262 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 34 | 0.050 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2002 | 84 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2002 | 75 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2015 | 138 | 0.050 |
Why?
|
| Breast | 2 | 2002 | 85 | 0.050 |
Why?
|
| Cerebral Infarction | 1 | 2001 | 34 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 2 | 2013 | 160 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2021 | 149 | 0.040 |
Why?
|
| Ectoderm | 1 | 2000 | 1 | 0.040 |
Why?
|
| Lovastatin | 1 | 2000 | 9 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2007 | 179 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 340 | 0.040 |
Why?
|
| Activin Receptors, Type I | 1 | 2000 | 2 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 111 | 0.040 |
Why?
|
| Ploidies | 1 | 2020 | 10 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2021 | 92 | 0.040 |
Why?
|
| Human papillomavirus 18 | 1 | 2020 | 9 | 0.040 |
Why?
|
| Receptors, Pituitary Hormone | 2 | 1998 | 2 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2001 | 111 | 0.040 |
Why?
|
| Sphingosine | 2 | 1997 | 34 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2017 | 879 | 0.040 |
Why?
|
| DNA, Complementary | 3 | 2005 | 135 | 0.040 |
Why?
|
| Risk | 2 | 2012 | 316 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2012 | 81 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2000 | 53 | 0.040 |
Why?
|
| Diabetic Foot | 1 | 2001 | 76 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2000 | 49 | 0.040 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 44 | 0.040 |
Why?
|
| G2 Phase | 1 | 2000 | 13 | 0.040 |
Why?
|
| Phorbol Esters | 1 | 2000 | 3 | 0.040 |
Why?
|
| DNA Footprinting | 1 | 2000 | 9 | 0.040 |
Why?
|
| Alternative Splicing | 2 | 2016 | 62 | 0.040 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2000 | 11 | 0.040 |
Why?
|
| Bleomycin | 1 | 2020 | 38 | 0.040 |
Why?
|
| RNA-Binding Proteins | 2 | 2011 | 128 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 50 | 0.040 |
Why?
|
| Diamines | 1 | 2019 | 4 | 0.040 |
Why?
|
| Leg | 1 | 2000 | 120 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2019 | 29 | 0.040 |
Why?
|
| Azacitidine | 1 | 2019 | 39 | 0.040 |
Why?
|
| Ligands | 2 | 2000 | 206 | 0.040 |
Why?
|
| Deoxyribonuclease I | 1 | 2000 | 33 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 19 | 0.040 |
Why?
|
| Antigens, Neoplasm | 2 | 2009 | 147 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 1997 | 42 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2000 | 72 | 0.040 |
Why?
|
| Anemia, Aplastic | 1 | 2019 | 11 | 0.040 |
Why?
|
| Moloney murine leukemia virus | 2 | 1989 | 2 | 0.040 |
Why?
|
| Proteinuria | 1 | 2019 | 39 | 0.040 |
Why?
|
| Adiposity | 1 | 2021 | 143 | 0.040 |
Why?
|
| Viral Proteins | 1 | 1981 | 164 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2000 | 110 | 0.040 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1999 | 8 | 0.040 |
Why?
|
| Mullerian Ducts | 1 | 2019 | 4 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2019 | 10 | 0.040 |
Why?
|
| Immunoassay | 1 | 2019 | 23 | 0.040 |
Why?
|
| Onium Compounds | 1 | 1999 | 13 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 83 | 0.040 |
Why?
|
| Models, Economic | 1 | 2018 | 16 | 0.040 |
Why?
|
| Toxicity Tests, Subacute | 1 | 2018 | 1 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 104 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2004 | 272 | 0.040 |
Why?
|
| Ophthalmic Solutions | 1 | 2018 | 20 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2019 | 113 | 0.040 |
Why?
|
| Morphogenesis | 1 | 2018 | 18 | 0.040 |
Why?
|
| Acetylcysteine | 1 | 1999 | 102 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2019 | 114 | 0.040 |
Why?
|
| Erythroid Precursor Cells | 1 | 1998 | 15 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2001 | 473 | 0.040 |
Why?
|
| Cornea | 1 | 2018 | 53 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 3 | 2006 | 242 | 0.040 |
Why?
|
| Lymphoma | 1 | 1999 | 71 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 146 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1998 | 12 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2018 | 137 | 0.040 |
Why?
|
| Flavonoids | 1 | 1998 | 54 | 0.040 |
Why?
|
| Focal Adhesions | 1 | 2017 | 16 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 100 | 0.040 |
Why?
|
| Neuropilin-1 | 1 | 2017 | 2 | 0.040 |
Why?
|
| Receptor, TIE-2 | 1 | 2017 | 16 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 1998 | 46 | 0.040 |
Why?
|
| Estrogens | 1 | 1999 | 223 | 0.040 |
Why?
|
| Integrins | 1 | 2017 | 31 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 1999 | 246 | 0.040 |
Why?
|
| Permeability | 1 | 2017 | 66 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2017 | 30 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2017 | 19 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 56 | 0.040 |
Why?
|
| Microcirculation | 1 | 2017 | 64 | 0.040 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1998 | 60 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2009 | 552 | 0.040 |
Why?
|
| Chitosan | 1 | 2017 | 42 | 0.030 |
Why?
|
| Aging | 1 | 2002 | 701 | 0.030 |
Why?
|
| Neurons | 1 | 2000 | 418 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 19 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1997 | 13 | 0.030 |
Why?
|
| Telomere-Binding Proteins | 1 | 2017 | 6 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2001 | 412 | 0.030 |
Why?
|
| Thrombosis | 1 | 2000 | 253 | 0.030 |
Why?
|
| DNA Probes, HPV | 1 | 1997 | 3 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 235 | 0.030 |
Why?
|
| Micelles | 1 | 2017 | 8 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2018 | 187 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 29 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1991 | 96 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 64 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2017 | 90 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 1996 | 26 | 0.030 |
Why?
|
| Receptors, Vasoactive Intestinal Peptide | 1 | 1996 | 3 | 0.030 |
Why?
|
| Tubulin | 1 | 2016 | 21 | 0.030 |
Why?
|
| Tubulin Modulators | 1 | 2016 | 27 | 0.030 |
Why?
|
| Transformation, Genetic | 1 | 1996 | 17 | 0.030 |
Why?
|
| Laparoscopy | 1 | 2018 | 180 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2011 | 406 | 0.030 |
Why?
|
| Postmenopause | 2 | 2009 | 82 | 0.030 |
Why?
|
| Ondansetron | 1 | 2016 | 12 | 0.030 |
Why?
|
| Dimerization | 1 | 1996 | 51 | 0.030 |
Why?
|
| Tretinoin | 2 | 1994 | 54 | 0.030 |
Why?
|
| Phenanthridines | 1 | 1996 | 4 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 73 | 0.030 |
Why?
|
| NF-kappa B p50 Subunit | 2 | 2010 | 17 | 0.030 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1996 | 12 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1997 | 229 | 0.030 |
Why?
|
| Computers, Molecular | 1 | 2016 | 1 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 154 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1996 | 39 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 9 | 0.030 |
Why?
|
| Cytarabine | 1 | 1996 | 42 | 0.030 |
Why?
|
| Oncogene Proteins v-mos | 1 | 1995 | 1 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1995 | 5 | 0.030 |
Why?
|
| Cocarcinogenesis | 1 | 1996 | 14 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 160 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 1994 | 190 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2017 | 314 | 0.030 |
Why?
|
| Ultraviolet Rays | 2 | 2008 | 50 | 0.030 |
Why?
|
| Conserved Sequence | 2 | 2006 | 53 | 0.030 |
Why?
|
| Miniaturization | 1 | 2015 | 5 | 0.030 |
Why?
|
| Leukopenia | 1 | 2015 | 7 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2015 | 28 | 0.030 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 3 | 2000 | 14 | 0.030 |
Why?
|
| Tropism | 1 | 2015 | 2 | 0.030 |
Why?
|
| Receptors, Peptide | 1 | 2015 | 10 | 0.030 |
Why?
|
| Glioblastoma | 1 | 1997 | 97 | 0.030 |
Why?
|
| Drug Implants | 1 | 2015 | 35 | 0.030 |
Why?
|
| Inflammation | 2 | 2012 | 641 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 27 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1995 | 40 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 51 | 0.030 |
Why?
|
| Solubility | 1 | 2015 | 79 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2016 | 67 | 0.030 |
Why?
|
| Protein Transport | 1 | 2016 | 180 | 0.030 |
Why?
|
| Bombesin | 1 | 1995 | 2 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 1563 | 0.030 |
Why?
|
| Naphthalenes | 1 | 1996 | 121 | 0.030 |
Why?
|
| Oncogene Proteins v-raf | 1 | 1994 | 1 | 0.030 |
Why?
|
| Muscles | 1 | 2015 | 107 | 0.030 |
Why?
|
| Genetic Complementation Test | 2 | 1988 | 47 | 0.030 |
Why?
|
| Estradiol | 1 | 1996 | 214 | 0.030 |
Why?
|
| Smoking | 2 | 1996 | 520 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2016 | 348 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1994 | 69 | 0.030 |
Why?
|
| Algorithms | 1 | 2018 | 672 | 0.030 |
Why?
|
| Leucine Zippers | 1 | 1994 | 1 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2014 | 105 | 0.030 |
Why?
|
| Drug Industry | 1 | 2014 | 40 | 0.030 |
Why?
|
| Teratocarcinoma | 1 | 1993 | 1 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2013 | 15 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2009 | 202 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1995 | 164 | 0.030 |
Why?
|
| Cystadenoma | 1 | 1993 | 3 | 0.030 |
Why?
|
| DNA Methylation | 2 | 2010 | 592 | 0.030 |
Why?
|
| RNA Splicing | 2 | 1991 | 41 | 0.030 |
Why?
|
| Capsules | 1 | 2013 | 29 | 0.030 |
Why?
|
| Cell Shape | 1 | 2013 | 21 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 92 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 23 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2013 | 12 | 0.030 |
Why?
|
| Weight Loss | 1 | 2015 | 248 | 0.030 |
Why?
|
| Genes, Suppressor | 1 | 1993 | 2 | 0.030 |
Why?
|
| Software Design | 1 | 2013 | 13 | 0.030 |
Why?
|
| Nitrogen Oxides | 1 | 2013 | 3 | 0.030 |
Why?
|
| Ice | 1 | 2013 | 3 | 0.030 |
Why?
|
| Atmosphere | 1 | 2013 | 11 | 0.030 |
Why?
|
| Oxidants | 2 | 2003 | 51 | 0.030 |
Why?
|
| Adsorption | 1 | 2013 | 19 | 0.030 |
Why?
|
| DNA Fragmentation | 2 | 2004 | 55 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1993 | 90 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 69 | 0.030 |
Why?
|
| Plasmids | 2 | 1994 | 163 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 57 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2013 | 35 | 0.030 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 3 | 1998 | 13 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2013 | 40 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 1994 | 117 | 0.030 |
Why?
|
| Pressure | 1 | 2013 | 104 | 0.030 |
Why?
|
| Calcium | 1 | 2014 | 376 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 1993 | 88 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 1993 | 185 | 0.020 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1992 | 4 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2012 | 47 | 0.020 |
Why?
|
| Mass Screening | 1 | 1995 | 357 | 0.020 |
Why?
|
| Australia | 1 | 2012 | 89 | 0.020 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 1991 | 3 | 0.020 |
Why?
|
| Veratrum Alkaloids | 1 | 2011 | 5 | 0.020 |
Why?
|
| Carbohydrate Metabolism | 1 | 1992 | 23 | 0.020 |
Why?
|
| Retinal Dehydrogenase | 1 | 2011 | 10 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 451 | 0.020 |
Why?
|
| Equipment Design | 1 | 2013 | 293 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 2003 | 7 | 0.020 |
Why?
|
| Classification | 1 | 2011 | 12 | 0.020 |
Why?
|
| Granulocytes | 1 | 1991 | 27 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 1992 | 43 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2011 | 13 | 0.020 |
Why?
|
| Caspase 3 | 2 | 2003 | 95 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 605 | 0.020 |
Why?
|
| Cell Dedifferentiation | 1 | 2011 | 9 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2003 | 26 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 1991 | 69 | 0.020 |
Why?
|
| Adenoviridae | 2 | 2003 | 47 | 0.020 |
Why?
|
| Genetic Testing | 1 | 1992 | 129 | 0.020 |
Why?
|
| Estrous Cycle | 1 | 2011 | 5 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 227 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2011 | 54 | 0.020 |
Why?
|
| Hydrogen Peroxide | 2 | 2003 | 120 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 185 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 149 | 0.020 |
Why?
|
| COS Cells | 2 | 2003 | 73 | 0.020 |
Why?
|
| Texas | 1 | 2011 | 143 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 55 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 183 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2010 | 8 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 25 | 0.020 |
Why?
|
| Transcription Factor RelB | 1 | 2010 | 3 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 49 | 0.020 |
Why?
|
| Carbolines | 1 | 2010 | 4 | 0.020 |
Why?
|
| Adenoma | 1 | 1992 | 113 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 2 | 2000 | 10 | 0.020 |
Why?
|
| Caspase Inhibitors | 2 | 2000 | 16 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 265 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 104 | 0.020 |
Why?
|
| CHO Cells | 1 | 2010 | 125 | 0.020 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1990 | 25 | 0.020 |
Why?
|
| Cricetinae | 1 | 2010 | 194 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2000 | 49 | 0.020 |
Why?
|
| Minority Health | 1 | 2009 | 10 | 0.020 |
Why?
|
| Financing, Government | 1 | 2009 | 23 | 0.020 |
Why?
|
| Child | 1 | 2022 | 7248 | 0.020 |
Why?
|
| Guanosine Triphosphate | 2 | 2000 | 17 | 0.020 |
Why?
|
| Ovarian Cysts | 1 | 2009 | 4 | 0.020 |
Why?
|
| Mucin-1 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Sodium Salicylate | 1 | 2009 | 4 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1989 | 47 | 0.020 |
Why?
|
| Gastrin-Releasing Peptide | 3 | 1995 | 3 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2009 | 30 | 0.020 |
Why?
|
| Acetamides | 1 | 1989 | 19 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 78 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1989 | 90 | 0.020 |
Why?
|
| Suppression, Genetic | 1 | 1989 | 3 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2009 | 42 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Leukemia, Myeloid | 2 | 2000 | 42 | 0.020 |
Why?
|
| Chromones | 1 | 2008 | 17 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2009 | 125 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 102 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2008 | 61 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 115 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 313 | 0.020 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2000 | 32 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2008 | 108 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 154 | 0.020 |
Why?
|
| Tocopherols | 2 | 1998 | 6 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2008 | 50 | 0.020 |
Why?
|
| Aldehyde Reductase | 1 | 2007 | 3 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 727 | 0.020 |
Why?
|
| GABA Plasma Membrane Transport Proteins | 1 | 2007 | 3 | 0.020 |
Why?
|
| Aquaporin 2 | 1 | 2007 | 5 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2008 | 40 | 0.020 |
Why?
|
| Symporters | 1 | 2007 | 15 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2008 | 79 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1988 | 24 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 1991 | 194 | 0.020 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide | 2 | 1998 | 2 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2007 | 25 | 0.020 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2007 | 19 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2007 | 56 | 0.020 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 61 | 0.020 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2007 | 5 | 0.020 |
Why?
|
| Dogs | 1 | 2007 | 180 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 56 | 0.020 |
Why?
|
| Serum Response Element | 1 | 2006 | 4 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2006 | 23 | 0.020 |
Why?
|
| Cyclic AMP | 2 | 1998 | 91 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2007 | 115 | 0.020 |
Why?
|
| Iodine Radioisotopes | 2 | 1997 | 34 | 0.020 |
Why?
|
| Oligopeptides | 2 | 1999 | 92 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 107 | 0.020 |
Why?
|
| Collagen | 1 | 2007 | 211 | 0.020 |
Why?
|
| Forecasting | 1 | 2006 | 154 | 0.020 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 2 | 1998 | 10 | 0.020 |
Why?
|
| Epidermal Growth Factor | 2 | 1997 | 36 | 0.020 |
Why?
|
| Cell Nucleolus | 1 | 2005 | 3 | 0.020 |
Why?
|
| Serine | 2 | 1998 | 36 | 0.020 |
Why?
|
| Protein Prenylation | 1 | 2005 | 5 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2005 | 76 | 0.010 |
Why?
|
| Heterocyclic Compounds | 1 | 2005 | 28 | 0.010 |
Why?
|
| Gadolinium | 1 | 2005 | 44 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 2005 | 43 | 0.010 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 1 | 2004 | 1 | 0.010 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2004 | 3 | 0.010 |
Why?
|
| GATA1 Transcription Factor | 1 | 2004 | 7 | 0.010 |
Why?
|
| K562 Cells | 1 | 2004 | 42 | 0.010 |
Why?
|
| Carotid Stenosis | 1 | 2005 | 66 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 72 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2004 | 29 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2004 | 20 | 0.010 |
Why?
|
| Thiourea | 1 | 2004 | 7 | 0.010 |
Why?
|
| Glioma | 1 | 2005 | 78 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2004 | 44 | 0.010 |
Why?
|
| Electrosurgery | 1 | 2004 | 9 | 0.010 |
Why?
|
| Phosphatidylserines | 1 | 2003 | 3 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 48 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 253 | 0.010 |
Why?
|
| Mitogens | 1 | 2003 | 8 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 1884 | 0.010 |
Why?
|
| Carbazoles | 1 | 2003 | 18 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2003 | 94 | 0.010 |
Why?
|
| Polylysine | 1 | 2003 | 1 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 2003 | 3 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2003 | 44 | 0.010 |
Why?
|
| Sp1 Transcription Factor | 1 | 2002 | 20 | 0.010 |
Why?
|
| eIF-2 Kinase | 1 | 2002 | 11 | 0.010 |
Why?
|
| Biological Assay | 1 | 2003 | 47 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2002 | 5 | 0.010 |
Why?
|
| Europe | 1 | 2002 | 87 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2002 | 28 | 0.010 |
Why?
|
| Sputum | 2 | 1993 | 69 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2003 | 62 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 2 | 1999 | 288 | 0.010 |
Why?
|
| Age of Onset | 1 | 2002 | 110 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 174 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2002 | 139 | 0.010 |
Why?
|
| Adolescent | 1 | 1993 | 6739 | 0.010 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2003 | 190 | 0.010 |
Why?
|
| KB Cells | 1 | 2001 | 5 | 0.010 |
Why?
|
| Epitopes | 1 | 1981 | 65 | 0.010 |
Why?
|
| Skin | 2 | 1995 | 422 | 0.010 |
Why?
|
| Distemper Virus, Canine | 1 | 1981 | 1 | 0.010 |
Why?
|
| SSPE Virus | 1 | 1981 | 1 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1981 | 8 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1981 | 6 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1981 | 36 | 0.010 |
Why?
|
| Mitotic Index | 1 | 2000 | 7 | 0.010 |
Why?
|
| DNA, Antisense | 1 | 2000 | 2 | 0.010 |
Why?
|
| Genes, cdc | 1 | 2000 | 6 | 0.010 |
Why?
|
| Phosphoserine | 1 | 2000 | 5 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2000 | 45 | 0.010 |
Why?
|
| Transcription Factor CHOP | 1 | 2000 | 7 | 0.010 |
Why?
|
| Cell Size | 1 | 2000 | 45 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2000 | 29 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2000 | 23 | 0.010 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2000 | 6 | 0.010 |
Why?
|
| Hematoxylin | 1 | 2000 | 7 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2000 | 21 | 0.010 |
Why?
|
| Sarcoma, Ewing | 1 | 2000 | 28 | 0.010 |
Why?
|
| Renal Artery | 1 | 2000 | 32 | 0.010 |
Why?
|
| Suction | 1 | 2000 | 24 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 2000 | 39 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1981 | 230 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2000 | 10 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 192 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1980 | 39 | 0.010 |
Why?
|
| Angiography | 1 | 2000 | 114 | 0.010 |
Why?
|
| Spleen | 1 | 1981 | 172 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2000 | 13 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2000 | 70 | 0.010 |
Why?
|
| Arteries | 1 | 2000 | 92 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2000 | 91 | 0.010 |
Why?
|
| Stroke | 1 | 2005 | 512 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2000 | 72 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2000 | 117 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2000 | 288 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1999 | 21 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1999 | 21 | 0.010 |
Why?
|
| Tetracycline | 1 | 1999 | 20 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1999 | 29 | 0.010 |
Why?
|
| Registries | 1 | 2002 | 581 | 0.010 |
Why?
|
| Prevalence | 1 | 2002 | 1006 | 0.010 |
Why?
|
| Acute Disease | 1 | 2000 | 373 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2000 | 206 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1998 | 22 | 0.010 |
Why?
|
| G-Box Binding Factors | 1 | 1998 | 1 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1998 | 101 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 1998 | 28 | 0.010 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I | 1 | 1998 | 2 | 0.010 |
Why?
|
| Glycogen Synthase Kinases | 1 | 1998 | 1 | 0.010 |
Why?
|
| Leukemia | 1 | 1998 | 67 | 0.010 |
Why?
|
| Hepatocyte Growth Factor | 1 | 1998 | 11 | 0.010 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 1998 | 11 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 1 | 1998 | 34 | 0.010 |
Why?
|
| Erythropoietin | 1 | 1998 | 50 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1998 | 54 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1997 | 8 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 1998 | 101 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1998 | 129 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1998 | 163 | 0.010 |
Why?
|
| Sequence Homology | 1 | 1997 | 16 | 0.010 |
Why?
|
| Trans-Activators | 1 | 1998 | 135 | 0.010 |
Why?
|
| Benzophenanthridines | 1 | 1996 | 2 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1996 | 19 | 0.010 |
Why?
|
| Cytotoxins | 1 | 1996 | 15 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 1996 | 2 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1996 | 27 | 0.010 |
Why?
|
| Alkaloids | 1 | 1996 | 35 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 1996 | 34 | 0.010 |
Why?
|
| Cattle | 1 | 1996 | 205 | 0.010 |
Why?
|
| Ionomycin | 1 | 1995 | 4 | 0.010 |
Why?
|
| Skin Physiological Phenomena | 1 | 1995 | 15 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1995 | 61 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1996 | 176 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1994 | 42 | 0.010 |
Why?
|
| Fluocinolone Acetonide | 1 | 1994 | 5 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1993 | 117 | 0.010 |
Why?
|
| Gastrins | 1 | 1993 | 6 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 1992 | 20 | 0.010 |
Why?
|
| Friend murine leukemia virus | 1 | 1992 | 2 | 0.010 |
Why?
|
| Isotretinoin | 1 | 1992 | 8 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 1992 | 77 | 0.010 |
Why?
|
| Single-Strand Specific DNA and RNA Endonucleases | 1 | 1990 | 4 | 0.010 |
Why?
|
| Hormones, Ectopic | 1 | 1990 | 2 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1990 | 41 | 0.010 |
Why?
|
| Arginine Vasopressin | 1 | 1990 | 11 | 0.010 |
Why?
|
| Hyponatremia | 1 | 1990 | 12 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1989 | 5 | 0.010 |
Why?
|
| Carcinoid Tumor | 1 | 1989 | 15 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1989 | 19 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1989 | 38 | 0.000 |
Why?
|
| Heterozygote | 1 | 1989 | 90 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1988 | 82 | 0.000 |
Why?
|
| Half-Life | 1 | 1988 | 88 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 1981 | 3049 | 0.000 |
Why?
|
| Viral Interference | 1 | 1980 | 3 | 0.000 |
Why?
|
| RNA, Viral | 1 | 1980 | 127 | 0.000 |
Why?
|